Get the Stockscreener App
11.26
2.25%
-0.28
Astria Therapeutics Inc stock is traded at $11.26, with a volume of 42,510.
It is down -2.25% in the last 24 hours and down -4.97% over the past month.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$11.54
Open:
$11.49
24h Volume:
42,510
Relative Volume:
0.14
Market Cap:
$636.48M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
-4.6148
EPS:
-2.44
Net Cash Flow:
$-68.47M
1W Performance:
-5.92%
1M Performance:
-4.97%
6M Performance:
+18.12%
1Y Performance:
+128.34%
1-Day Range:
$11.19
$11.64
1-Week Range:
$11.01
$12.52
52-Week Range:
$4.26
$16.90
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617-349-1971
Address
22 BOSTON WHARF ROAD, BOSTON
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-24 | Initiated | TD Cowen | Buy |
| Mar-28-23 | Initiated | Evercore ISI | Outperform |
Astria Therapeutics Inc Stock (ATXS) Latest News
Vanguard Group Inc's Strategic Acquisition in Astria Therapeutics Inc - GuruFocus.com
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting - Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from Analysts - MarketBeat
Objective long/short (ATXS) Report - Stock Traders Daily
Astria Therapeutics (NASDAQ:ATXS) Shares Up 6.8%Here's What Happened - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - Business Wire
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth - Yahoo Finance
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema - BioSpace
Astria Therapeutics gains orphan drug status in EU for HAE treatment - Investing.com Australia
(ATXS) Trading Report - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Down 9.2% in September - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 4.1%Should You Sell? - MarketBeat
Renaissance Technologies LLC Decreases Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Dimensional Fund Advisors LP Buys 133,379 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Cubist Systematic Strategies LLC Purchases New Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Trading 5.2% HigherHere's What Happened - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Millennium Management LLC - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Rating of "Buy" by Analysts - MarketBeat
Insider Sale Alert: Astria Therapeutics Inc [ATXS] – Is it Time to sell? - Knox Daily
Nantahala Capital Management LLC Makes New $6.14 Million Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Are Astria Therapeutics Inc (ATXS) shares a good deal now? - US Post News
Closing Figures Unveiled: Astria Therapeutics Inc (ATXS) Drop -1.17, Closes at 11.01 - The Dwinnex
Logos Global Management LP Decreases Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
ATXSAstria Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema - StockTitan
Cubist Systematic Strategies LLC Invests $2.56 Million in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Driehaus Capital Management LLC Sells 15,057 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics (NASDAQ:ATXS) Earns Buy Rating from HC Wainwright - MarketBeat
Astria Therapeutics to Present at Upcoming Global Angioedema Forum - StockTitan
Financial Snapshot: Analyzing Astria Therapeutics Inc (ATXS)’s Key Ratio Metrics - The Dwinnex
ATXS’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Astria Therapeutics (NASDAQ:ATXS) Shares Gap Down to $12.50 - MarketBeat
Astria Therapeutics Inc [ATXS] Insider Morabito Christopher sells 10,000 Shares - Knox Daily
A year in review: Astria Therapeutics Inc (ATXS)’s performance in the last year - US Post News
Affinity Asset Advisors LLC Has $8.88 Million Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Affinity Asset Advisors LLC Buys 130,000 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Sold by Logos Global Management LP - Defense World
Logos Global Management LP Sells 1,744,960 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Long Term Trading Analysis for (ATXS) - Stock Traders Daily
Healthy Upside Potential: Astria Therapeutics Inc (ATXS) - SETE News
Quest Partners LLC Has $29,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astera Labs executive sells over $3.4 million in stock By Investing.com - Investing.com Canada
Investor’s Delight: Ascendis Pharma A/S ADR (ASND) Closes Strong at 148.88, Up 1.56 - The Dwinnex
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress - StockTitan
Equities Analysts Set Expectations for Ascendis Pharma A/S’s Q3 2024 Earnings (NASDAQ:ASND) - Defense World
Ascendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Seven Eight Capital LP - MarketBeat
APRE stock touches 52-week low at $2.86 amid market challenges - Investing.com
Astria Therapeutics Inc Stock (ATXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Astria Therapeutics Inc Stock (ATXS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morabito Christopher | Chief Medical Officer |
Apr 01 '24 |
Sale |
13.59 |
10,000 |
135,939 |
0 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 01 '24 |
Buy |
12.09 |
2,481,350 |
29,999,522 |
4,873,721 |
| Morabito Christopher | Chief Medical Officer |
Jan 29 '24 |
Option Exercise |
3.87 |
9,200 |
35,604 |
9,200 |
| Morabito Christopher | Chief Medical Officer |
Jan 26 '24 |
Option Exercise |
3.87 |
800 |
3,096 |
800 |
| Morabito Christopher | Chief Medical Officer |
Jan 29 '24 |
Sale |
11.15 |
9,200 |
102,552 |
0 |
| Morabito Christopher | Chief Medical Officer |
Jan 26 '24 |
Sale |
11.02 |
800 |
8,812 |
0 |
| PERCEPTIVE ADVISORS LLC | Director |
Dec 21 '23 |
Buy |
6.20 |
740,000 |
4,588,000 |
2,392,371 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):